Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia

Completed · Phase 2

Conditions studied: Acute Myelogenous Leukemia

In brief

The purpose of this study is to evaluate clinical and laboratory safety associated with the administration of GVAX leukemia vaccine and to determine the feasibility of generation of GVAX leukemia vaccine in subjects with acute myelogenous leukemia (AML).

Key facts

Study ID

NCT00116467

Run by

Cell Genesys

People needed

55

Starts

2001-03-01

Expected to finish

2006-01-01

Last updated by the study team

2007-12-24

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Initial diagnosis of de novo AML with no preexisting hematologic dysplasia for more than 3 months.
• No prior therapy except leukapheresis or less than 72 hours of hydroxyurea.

You may not qualify if…

• Prior myelodysplastic disorder, or treatment-related leukemia.
• Prior myeloproliferative disease.
• Acute promyelocytic leukemia (APL).
• Prior chemotherapy for a malignant or nonmalignant disorder.

Where it is running

• University of California, San Francisco — San Francisco, California, United States
• University of Chicago — Chicago, Illinois, United States
• Johns Hopkins University — Baltimore, Maryland, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.